Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Core Insights - Adverum Biotechnologies has appointed Dr. Romuald Corbau as the new Chief Scientific Officer, who will be part of the executive committee [1][2] - Dr. Corbau brings over 25 years of experience in gene therapy, having previously worked at Spark Therapeutics and GenEdit, and is expected to contribute significantly to Adverum's development of Ixo-vec for wet AMD [2][4] Company Overview - Adverum Biotechnologies is a clinical-stage company focused on establishing gene therapy as a new standard of care for prevalent ocular diseases, aiming to develop functional cures to restore vision and prevent blindness [4] - The company is developing Ixo-vec, a one-time intravitreal injection for patients with neovascular or wet age-related macular degeneration, with the goal of transforming the standard of care in ocular diseases [4] Leadership and Expertise - Dr. Corbau has a strong background in AAV-mediated gene therapies and ophthalmic research, which is expected to be invaluable as Adverum advances Ixo-vec toward pivotal trials and commercialization [2] - His previous roles include leading translational R&D for Luxturna® at Spark Therapeutics and serving as Chief Scientific Officer at GenEdit [2] Inducement Grant - On January 22, 2024, Adverum granted Dr. Corbau a stock option to purchase 600,000 shares of common stock as an inducement for his employment, with a vesting period of four years [3]